查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1140011

慢性疾病管理市場:各類型，各疾病類型，各終端用戶:全球機會分析及產業預測，2021-2031年

Chronic Disease Management Market By Type, By Disease Type, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 281 Pages | 商品交期: 2-3個工作天內

價格

全球慢性疾病管理市場，2021年達到48億9669萬美元，預計2031年達148億7548萬美元，從2022年到2031年以11.8％的年複合成長率成長。

推動市場成長的關鍵因素是對醫療保健管理服務意識的提高以及癌症、心臟病、糖尿病、高血壓等慢性病患病率的上升。根據世界衛生組織的報告，2021年，非傳染性疾病 (NCD) 每年造成約4100萬人死亡，佔全球死亡人數的71%。此外，服務提供者的服務改善增加了市場對慢病管理服務的需求。醫療旅遊業的成長和醫療保健IT解決方案的興起推動了慢性病管理市場的成長。然而，缺乏熟練的專業人員和高昂的治療成本，以及對管理系統/工具的高投資阻礙了市場的成長。

目錄

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 主要調查結果
    • 主要的投資口袋
  • 波特的五力分析
  • 主要企業的定位
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
  • COVID-19的影響分析

第4章 慢性疾病管理市場:各類型

  • 概要
    • 市場規模及預測
  • 解決方案
    • 主要的市場趨勢，成長要素，機會
    • 市場規模、預測:各地區
    • 市場分析:各國分析
  • 服務
    • 主要的市場趨勢，成長要素，機會
    • 市場規模、預測:各地區
    • 市場分析:各國

第5章 慢性疾病管理市場:各疾病類型

  • 概要
    • 市場規模及預測
  • 循環系統系疾病
    • 主要的市場趨勢，成長要素，機會
    • 市場規模及預測:各地區
    • 市場分析:各國
  • 糖尿病領域
    • 主要的市場趨勢，成長要素，機會
    • 市場規模、預測:各地區
    • 市場分析:各國
  • 癌症
    • 主要的市場趨勢，成長要素，機會
    • 市場規模、預測:各地區
    • 市場分析:各國
  • 支氣管氣喘
    • 主要的市場趨勢，成長要素，機會
    • 市場規模、預測:各地區
    • 市場分析:各國
  • 慢性阻塞性肺病
    • 主要的市場趨勢，成長要素，機會
    • 市場規模、預測:各地區
    • 市場分析:各國
  • 其他
    • 主要的市場趨勢，成長要素，機會
    • 市場規模、預測:各地區
    • 市場分析:各國

第6章 慢性疾病管理市場:各終端用戶

  • 概要
    • 市場規模、預測
  • 醫療保健供應商
    • 主要的市場趨勢，成長要素與機會
    • 市場規模、預測:各地區
    • 市場分析:各國
  • 醫療保健支付者
    • 主要的市場趨勢，成長要素，機會
    • 市場規模、預測:各地區
    • 市場分析:各國
  • 其他
    • 主要的市場趨勢，成長要素，機會
    • 市場規模、預測:各地區
    • 市場分析:各國

第7章 慢性疾病管理市場:各地區

  • 概要
    • 市場規模、預測
  • 北美
    • 主要趨勢和機會
    • 北美市場規模、預測:各類型
    • 北美市場規模、預測:各疾病類型
    • 北美市場規模、預測:各終端用戶
    • 北美市場規模、預測:各國
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要趨勢和機會
    • 歐洲的市場規模、預測:各類型
    • 歐洲市場規模、預測:各疾病類型
    • 歐洲市場規模、預測:各終端用戶
    • 歐洲市場規模、預測:各國
      • 德國
      • 法國
      • 英國
      • 義大利
      • 西班牙
      • 其他的歐洲地區
  • 亞太地區
    • 主要趨勢和機會
    • 亞太地區的市場規模、預測:各類型
    • 亞太地區的市場規模、預測:各疾病類型
    • 亞太地區的市場規模、預測:各終端用戶
    • 亞太地區的市場規模、預測:各國
      • 日本
      • 中國
      • 澳洲
      • 印度
      • 韓國
      • 其他亞太地區
  • LAMEA
    • 主要趨勢和機會
    • LAMEA的市場規模、預測:各類型
    • LAMEA的市場規模、預測:各疾病類型
    • LAMEA的市場規模、預測:各終端用戶
    • LAMEA的市場規模、預測:各國
      • 巴西
      • 沙烏地阿拉伯
      • 南非
      • LAMEA的其餘地區

第8章 企業形勢

  • 簡介
  • 主要成功策略
  • 主要十大公司的產品製圖
  • 競爭儀表板
  • 競爭的熱圖
  • 主要的發展

第9章 企業簡介

  • Koninklijke Philips N.V
  • Cognizant TriZetto Software Group Inc,
  • Cedar Gate Technologies
  • Casenet, LLC
  • cliexa, Inc
  • Altruista Health
  • Infosys Ltd
  • Pegasystems Inc
  • Epic Systems Corporation
  • Hinduja Global Solutions Ltd
  • NXGN Management, LLC
  • ExlServings Holdings, Inc
  • Vivify Health, Inc
  • Allscripts Healthcare, LLC
  • Medecision
  • ZeOmega
  • Health Catalyst
Product Code: A12327

The global chronic disease management market was valued at $4,896.69 million in 2021 and is projected to reach $14,875.48 million by 2031, registering a CAGR of 11.8% from 2022 to 2031.

Chronic disease management is an integrated care approach to managing the illness, which includes screenings, check-ups, monitoring and coordinating treatment, and patient education. It can improve the quality of life, while reducing healthcare costs. Chronic disease management programs are designed to improve the health of individuals with chronic conditions and reduce associated costs from avoidable complications by identifying and treating chronic conditions more quickly and more effectively; thus slowing the progression of those diseases. 

The key factors that drive the growth of the market are an increase in awareness regarding the healthcare management service and a rise in the prevalence of chronic diseases such as cancer, heart disease, diabetes, high blood pressure, and others. According to a report published by the World Health Organization, in 2021, non-communicable diseases (NCDs) killed around 41 million people each year, which was 71% of all deaths globally. Moreover, improved services by the service provider have increased the demand for chronic disease management services in the market. The growth in the medical tourism sector and the rise in healthcare IT solutions drive the growth of the chronic disease management market. However, a lack of skilled professionals and high cost of treatment, and high investment in the management system/tools hinder the growth of the market. 

The chronic disease management market is segmented on the basis of type, disease type, end user, and region. By type, the market is bifurcated into solutions and services. The solution segment is further classified on the basis of an on-premise solution and a cloud-based solution. On the basis of service, the segment is segmented into educational service, implementation service, and consulting service. On the basis of disease type, the segment is divided into cardiovascular disease, diabetes, cancer, asthma, a chronic obstructive pulmonary disorder, and others. On the basis of end-user, the segment is divided into providers, payers, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

North America accounted for a majority of the chronic disease management market share in 2021 and is anticipated to remain dominant during the forecast period. The factors, such as favorable regulatory scenario, pressure on healthcare institutions to reduce costs, and rise in trends in healthcare IT, big data and cloud computing, well-established healthcare infrastructure, continuous reforms by governments, and an increase in diseased patient burden are driving the growth of the chronic disease management market in the regions.

For instance, the U.S. government implemented the Affordable Care Act (ACA) for the prevention of diseases and the adoption of healthcare IT. The ACA is expected to boost the growth of the chronic disease management market and create opportunities for population health management service providers to collect and maintain patients' data.

The key players that operate in the chronic disease management market are WellSky, ZeOmega, Health Catalyst, Cedar Gate Technologies, Cognizant, Pegasystems Inc., Epic Systems Corporation, Hinduja Global Solutions Ltd. (Bengaluru), NXGN Management, LLC, MINES & Associates, Inc., Casenet, LLC, ExlServings Holdings, Inc., cliexa., ScienceSoft USA Corporation, Vivify Health, Inc., Allscripts Healthcare, LLC, Infosys Limited, Medecision, IBM, Altruista Health, TCS Healthcare Technologies, and Koninklijke Philips N.V. (Netherlands

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the chronic disease management market analysis from 2021 to 2031 to identify the prevailing chronic disease management market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the chronic disease management market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global chronic disease management market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Disease Type

  • Cardiovascular diseases 
  • Diabetes
  • Cancer
  • Asthma
  • Chronic obstructive pulmonary disorders
  • Others

By Type

  • Solutions
  • Services

By End User

  • Healthcare Providers
  • Healthcare Payers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Italy
    • Spain
    • Rest of Europe
    • Germany
    • France
    • U.K.
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest Of Asia Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Koninklijke Philips N.V
    • Cognizant TriZetto Software Group Inc,
    • Cedar Gate Technologies
    • Casenet, LLC
    • cliexa, Inc
    • Altruista Health
    • Infosys Ltd
    • Pegasystems Inc
    • Epic Systems Corporation
    • Hinduja Global Solutions Ltd
    • NXGN Management, LLC
    • ExlServings Holdings, Inc
    • Vivify Health, Inc
    • Allscripts Healthcare, LLC
    • Medecision
    • ZeOmega
    • Health Catalyst

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Solutions
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Services
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country

CHAPTER 5: CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Cardiovascular diseases 
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Diabetes
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Cancer
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country
  • 5.5 Asthma
    • 5.5.1 Key market trends, growth factors and opportunities
    • 5.5.2 Market size and forecast, by region
    • 5.5.3 Market analysis by country
  • 5.6 Chronic obstructive pulmonary disorders
    • 5.6.1 Key market trends, growth factors and opportunities
    • 5.6.2 Market size and forecast, by region
    • 5.6.3 Market analysis by country
  • 5.7 Others
    • 5.7.1 Key market trends, growth factors and opportunities
    • 5.7.2 Market size and forecast, by region
    • 5.7.3 Market analysis by country

CHAPTER 6: CHRONIC DISEASE MANAGEMENT MARKET, BY END USER

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Healthcare Providers
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Healthcare Payers
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Others
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: CHRONIC DISEASE MANAGEMENT MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Type
    • 7.2.3 North America Market size and forecast, by Disease Type
    • 7.2.4 North America Market size and forecast, by End User
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Type
      • 7.2.5.1.2 Market size and forecast, by Disease Type
      • 7.2.5.1.3 Market size and forecast, by End User
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Type
      • 7.2.5.2.2 Market size and forecast, by Disease Type
      • 7.2.5.2.3 Market size and forecast, by End User
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Type
      • 7.2.5.3.2 Market size and forecast, by Disease Type
      • 7.2.5.3.3 Market size and forecast, by End User
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Type
    • 7.3.3 Europe Market size and forecast, by Disease Type
    • 7.3.4 Europe Market size and forecast, by End User
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Type
      • 7.3.5.1.2 Market size and forecast, by Disease Type
      • 7.3.5.1.3 Market size and forecast, by End User
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Type
      • 7.3.5.2.2 Market size and forecast, by Disease Type
      • 7.3.5.2.3 Market size and forecast, by End User
      • 7.3.5.3 U.K.
      • 7.3.5.3.1 Market size and forecast, by Type
      • 7.3.5.3.2 Market size and forecast, by Disease Type
      • 7.3.5.3.3 Market size and forecast, by End User
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Type
      • 7.3.5.4.2 Market size and forecast, by Disease Type
      • 7.3.5.4.3 Market size and forecast, by End User
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Type
      • 7.3.5.5.2 Market size and forecast, by Disease Type
      • 7.3.5.5.3 Market size and forecast, by End User
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Type
      • 7.3.5.6.2 Market size and forecast, by Disease Type
      • 7.3.5.6.3 Market size and forecast, by End User
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Disease Type
    • 7.4.4 Asia-Pacific Market size and forecast, by End User
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Type
      • 7.4.5.1.2 Market size and forecast, by Disease Type
      • 7.4.5.1.3 Market size and forecast, by End User
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Type
      • 7.4.5.2.2 Market size and forecast, by Disease Type
      • 7.4.5.2.3 Market size and forecast, by End User
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Market size and forecast, by Type
      • 7.4.5.3.2 Market size and forecast, by Disease Type
      • 7.4.5.3.3 Market size and forecast, by End User
      • 7.4.5.4 India
      • 7.4.5.4.1 Market size and forecast, by Type
      • 7.4.5.4.2 Market size and forecast, by Disease Type
      • 7.4.5.4.3 Market size and forecast, by End User
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Type
      • 7.4.5.5.2 Market size and forecast, by Disease Type
      • 7.4.5.5.3 Market size and forecast, by End User
      • 7.4.5.6 Rest Of Asia Pacific
      • 7.4.5.6.1 Market size and forecast, by Type
      • 7.4.5.6.2 Market size and forecast, by Disease Type
      • 7.4.5.6.3 Market size and forecast, by End User
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Type
    • 7.5.3 LAMEA Market size and forecast, by Disease Type
    • 7.5.4 LAMEA Market size and forecast, by End User
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Type
      • 7.5.5.1.2 Market size and forecast, by Disease Type
      • 7.5.5.1.3 Market size and forecast, by End User
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Type
      • 7.5.5.2.2 Market size and forecast, by Disease Type
      • 7.5.5.2.3 Market size and forecast, by End User
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Type
      • 7.5.5.3.2 Market size and forecast, by Disease Type
      • 7.5.5.3.3 Market size and forecast, by End User
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Type
      • 7.5.5.4.2 Market size and forecast, by Disease Type
      • 7.5.5.4.3 Market size and forecast, by End User

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Koninklijke Philips N.V
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Cognizant TriZetto Software Group Inc,
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Cedar Gate Technologies
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Casenet, LLC
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 cliexa, Inc
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Altruista Health
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Infosys Ltd
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Pegasystems Inc
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Epic Systems Corporation
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Hinduja Global Solutions Ltd
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments
  • 9.11 NXGN Management, LLC
    • 9.11.1 Company overview
    • 9.11.2 Company snapshot
    • 9.11.3 Operating business segments
    • 9.11.4 Product portfolio
    • 9.11.5 Business performance
    • 9.11.6 Key strategic moves and developments
  • 9.12 ExlServings Holdings, Inc
    • 9.12.1 Company overview
    • 9.12.2 Company snapshot
    • 9.12.3 Operating business segments
    • 9.12.4 Product portfolio
    • 9.12.5 Business performance
    • 9.12.6 Key strategic moves and developments
  • 9.13 Vivify Health, Inc
    • 9.13.1 Company overview
    • 9.13.2 Company snapshot
    • 9.13.3 Operating business segments
    • 9.13.4 Product portfolio
    • 9.13.5 Business performance
    • 9.13.6 Key strategic moves and developments
  • 9.14 Allscripts Healthcare, LLC
    • 9.14.1 Company overview
    • 9.14.2 Company snapshot
    • 9.14.3 Operating business segments
    • 9.14.4 Product portfolio
    • 9.14.5 Business performance
    • 9.14.6 Key strategic moves and developments
  • 9.15 Medecision
    • 9.15.1 Company overview
    • 9.15.2 Company snapshot
    • 9.15.3 Operating business segments
    • 9.15.4 Product portfolio
    • 9.15.5 Business performance
    • 9.15.6 Key strategic moves and developments
  • 9.16 ZeOmega
    • 9.16.1 Company overview
    • 9.16.2 Company snapshot
    • 9.16.3 Operating business segments
    • 9.16.4 Product portfolio
    • 9.16.5 Business performance
    • 9.16.6 Key strategic moves and developments
  • 9.17 Health Catalyst
    • 9.17.1 Company overview
    • 9.17.2 Company snapshot
    • 9.17.3 Operating business segments
    • 9.17.4 Product portfolio
    • 9.17.5 Business performance
    • 9.17.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 2. CHRONIC DISEASE MANAGEMENT MARKET SIZE, FOR SOLUTIONS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. CHRONIC DISEASE MANAGEMENT MARKET FOR SOLUTIONS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. CHRONIC DISEASE MANAGEMENT MARKET SIZE, FOR SERVICES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. CHRONIC DISEASE MANAGEMENT MARKET FOR SERVICES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 7. CHRONIC DISEASE MANAGEMENT MARKET SIZE, FOR CARDIOVASCULAR DISEASES , BY REGION, 2021-2031 ($MILLION)
  • TABLE 8. CHRONIC DISEASE MANAGEMENT MARKET FOR CARDIOVASCULAR DISEASES , BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 9. CHRONIC DISEASE MANAGEMENT MARKET SIZE, FOR DIABETES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. CHRONIC DISEASE MANAGEMENT MARKET FOR DIABETES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 11. CHRONIC DISEASE MANAGEMENT MARKET SIZE, FOR CANCER, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. CHRONIC DISEASE MANAGEMENT MARKET FOR CANCER, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 13. CHRONIC DISEASE MANAGEMENT MARKET SIZE, FOR ASTHMA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. CHRONIC DISEASE MANAGEMENT MARKET FOR ASTHMA, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 15. CHRONIC DISEASE MANAGEMENT MARKET SIZE, FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 16. CHRONIC DISEASE MANAGEMENT MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 17. CHRONIC DISEASE MANAGEMENT MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 18. CHRONIC DISEASE MANAGEMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 19. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 20. CHRONIC DISEASE MANAGEMENT MARKET SIZE, FOR HEALTHCARE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 21. CHRONIC DISEASE MANAGEMENT MARKET FOR HEALTHCARE PROVIDERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 22. CHRONIC DISEASE MANAGEMENT MARKET SIZE, FOR HEALTHCARE PAYERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 23. CHRONIC DISEASE MANAGEMENT MARKET FOR HEALTHCARE PAYERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 24. CHRONIC DISEASE MANAGEMENT MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 25. CHRONIC DISEASE MANAGEMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 26. CHRONIC DISEASE MANAGEMENT MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 27. NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 28. NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 29. NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 30. NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 31. U.S. CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 32. U.S. CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 33. U.S. CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 34. CANADA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 35. CANADA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 36. CANADA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 37. MEXICO CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 38. MEXICO CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 39. MEXICO CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 40. EUROPE CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 41. EUROPE CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 42. EUROPE CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 43. EUROPE CHRONIC DISEASE MANAGEMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 44. GERMANY CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 45. GERMANY CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 46. GERMANY CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 47. FRANCE CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 48. FRANCE CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 49. FRANCE CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 50. U.K. CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 51. U.K. CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 52. U.K. CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 53. ITALY CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 54. ITALY CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 55. ITALY CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 56. SPAIN CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 57. SPAIN CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 58. SPAIN CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 59. REST OF EUROPE CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 60. REST OF EUROPE CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 61. REST OF EUROPE CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 62. ASIA-PACIFIC CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 63. ASIA-PACIFIC CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 64. ASIA-PACIFIC CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 65. ASIA-PACIFIC CHRONIC DISEASE MANAGEMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 66. JAPAN CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 67. JAPAN CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 68. JAPAN CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 69. CHINA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 70. CHINA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 71. CHINA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 72. AUSTRALIA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 73. AUSTRALIA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 74. AUSTRALIA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 75. INDIA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 76. INDIA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 77. INDIA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 78. SOUTH KOREA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 79. SOUTH KOREA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 80. SOUTH KOREA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 81. REST OF ASIA PACIFIC CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 84. LAMEA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 85. LAMEA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 86. LAMEA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 87. LAMEA CHRONIC DISEASE MANAGEMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 88. BRAZIL CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 89. BRAZIL CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 90. BRAZIL CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 91. SAUDI ARABIA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 92. SAUDI ARABIA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 93. SAUDI ARABIA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 94. SOUTH AFRICA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 95. SOUTH AFRICA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 96. SOUTH AFRICA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 97. REST OF LAMEA CHRONIC DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 98. REST OF LAMEA CHRONIC DISEASE MANAGEMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 99. REST OF LAMEA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 100.KONINKLIJKE PHILIPS N.V: COMPANY SNAPSHOT
  • TABLE 101.KONINKLIJKE PHILIPS N.V: OPERATING SEGMENTS
  • TABLE 102.KONINKLIJKE PHILIPS N.V: PRODUCT PORTFOLIO
  • TABLE 103.KONINKLIJKE PHILIPS N.V: NET SALES,
  • TABLE 104.KONINKLIJKE PHILIPS N.V: KEY STRATERGIES
  • TABLE 105.COGNIZANT TRIZETTO SOFTWARE GROUP INC,: COMPANY SNAPSHOT
  • TABLE 106.COGNIZANT TRIZETTO SOFTWARE GROUP INC,: OPERATING SEGMENTS
  • TABLE 107.COGNIZANT TRIZETTO SOFTWARE GROUP INC,: PRODUCT PORTFOLIO
  • TABLE 108.COGNIZANT TRIZETTO SOFTWARE GROUP INC,: NET SALES,
  • TABLE 109.COGNIZANT TRIZETTO SOFTWARE GROUP INC,: KEY STRATERGIES
  • TABLE 110.CEDAR GATE TECHNOLOGIES: COMPANY SNAPSHOT
  • TABLE 111.CEDAR GATE TECHNOLOGIES: OPERATING SEGMENTS
  • TABLE 112.CEDAR GATE TECHNOLOGIES: PRODUCT PORTFOLIO
  • TABLE 113.CEDAR GATE TECHNOLOGIES: NET SALES,
  • TABLE 114.CEDAR GATE TECHNOLOGIES: KEY STRATERGIES
  • TABLE 115.CASENET, LLC: COMPANY SNAPSHOT
  • TABLE 116.CASENET, LLC: OPERATING SEGMENTS
  • TABLE 117.CASENET, LLC: PRODUCT PORTFOLIO
  • TABLE 118.CASENET, LLC: NET SALES,
  • TABLE 119.CASENET, LLC: KEY STRATERGIES
  • TABLE 120.CLIEXA, INC: COMPANY SNAPSHOT
  • TABLE 121.CLIEXA, INC: OPERATING SEGMENTS
  • TABLE 122.CLIEXA, INC: PRODUCT PORTFOLIO
  • TABLE 123.CLIEXA, INC: NET SALES,
  • TABLE 124.CLIEXA, INC: KEY STRATERGIES
  • TABLE 125.ALTRUISTA HEALTH: COMPANY SNAPSHOT
  • TABLE 126.ALTRUISTA HEALTH: OPERATING SEGMENTS
  • TABLE 127.ALTRUISTA HEALTH: PRODUCT PORTFOLIO
  • TABLE 128.ALTRUISTA HEALTH: NET SALES,
  • TABLE 129.ALTRUISTA HEALTH: KEY STRATERGIES
  • TABLE 130.INFOSYS LTD: COMPANY SNAPSHOT
  • TABLE 131.INFOSYS LTD: OPERATING SEGMENTS
  • TABLE 132.INFOSYS LTD: PRODUCT PORTFOLIO
  • TABLE 133.INFOSYS LTD: NET SALES,
  • TABLE 134.INFOSYS LTD: KEY STRATERGIES
  • TABLE 135.PEGASYSTEMS INC: COMPANY SNAPSHOT
  • TABLE 136.PEGASYSTEMS INC: OPERATING SEGMENTS
  • TABLE 137.PEGASYSTEMS INC: PRODUCT PORTFOLIO
  • TABLE 138.PEGASYSTEMS INC: NET SALES,
  • TABLE 139.PEGASYSTEMS INC: KEY STRATERGIES
  • TABLE 140.EPIC SYSTEMS CORPORATION: COMPANY SNAPSHOT
  • TABLE 141.EPIC SYSTEMS CORPORATION: OPERATING SEGMENTS
  • TABLE 142.EPIC SYSTEMS CORPORATION: PRODUCT PORTFOLIO
  • TABLE 143.EPIC SYSTEMS CORPORATION: NET SALES,
  • TABLE 144.EPIC SYSTEMS CORPORATION: KEY STRATERGIES
  • TABLE 145.HINDUJA GLOBAL SOLUTIONS LTD: COMPANY SNAPSHOT
  • TABLE 146.HINDUJA GLOBAL SOLUTIONS LTD: OPERATING SEGMENTS
  • TABLE 147.HINDUJA GLOBAL SOLUTIONS LTD: PRODUCT PORTFOLIO
  • TABLE 148.HINDUJA GLOBAL SOLUTIONS LTD: NET SALES,
  • TABLE 149.HINDUJA GLOBAL SOLUTIONS LTD: KEY STRATERGIES
  • TABLE 150.NXGN MANAGEMENT, LLC: COMPANY SNAPSHOT
  • TABLE 151.NXGN MANAGEMENT, LLC: OPERATING SEGMENTS
  • TABLE 152.NXGN MANAGEMENT, LLC: PRODUCT PORTFOLIO
  • TABLE 153.NXGN MANAGEMENT, LLC: NET SALES,
  • TABLE 154.NXGN MANAGEMENT, LLC: KEY STRATERGIES
  • TABLE 155.EXLSERVINGS HOLDINGS, INC: COMPANY SNAPSHOT
  • TABLE 156.EXLSERVINGS HOLDINGS, INC: OPERATING SEGMENTS
  • TABLE 157.EXLSERVINGS HOLDINGS, INC: PRODUCT PORTFOLIO
  • TABLE 158.EXLSERVINGS HOLDINGS, INC: NET SALES,
  • TABLE 159.EXLSERVINGS HOLDINGS, INC: KEY STRATERGIES
  • TABLE 160.VIVIFY HEALTH, INC: COMPANY SNAPSHOT
  • TABLE 161.VIVIFY HEALTH, INC: OPERATING SEGMENTS
  • TABLE 162.VIVIFY HEALTH, INC: PRODUCT PORTFOLIO
  • TABLE 163.VIVIFY HEALTH, INC: NET SALES,
  • TABLE 164.VIVIFY HEALTH, INC: KEY STRATERGIES
  • TABLE 165.ALLSCRIPTS HEALTHCARE, LLC: COMPANY SNAPSHOT
  • TABLE 166.ALLSCRIPTS HEALTHCARE, LLC: OPERATING SEGMENTS
  • TABLE 167.ALLSCRIPTS HEALTHCARE, LLC: PRODUCT PORTFOLIO
  • TABLE 168.ALLSCRIPTS HEALTHCARE, LLC: NET SALES,
  • TABLE 169.ALLSCRIPTS HEALTHCARE, LLC: KEY STRATERGIES
  • TABLE 170.MEDECISION: COMPANY SNAPSHOT
  • TABLE 171.MEDECISION: OPERATING SEGMENTS
  • TABLE 172.MEDECISION: PRODUCT PORTFOLIO
  • TABLE 173.MEDECISION: NET SALES,
  • TABLE 174.MEDECISION: KEY STRATERGIES
  • TABLE 175.ZEOMEGA: COMPANY SNAPSHOT
  • TABLE 176.ZEOMEGA: OPERATING SEGMENTS
  • TABLE 177.ZEOMEGA: PRODUCT PORTFOLIO
  • TABLE 178.ZEOMEGA: NET SALES,
  • TABLE 179.ZEOMEGA: KEY STRATERGIES
  • TABLE 180.HEALTH CATALYST: COMPANY SNAPSHOT
  • TABLE 181.HEALTH CATALYST: OPERATING SEGMENTS
  • TABLE 182.HEALTH CATALYST: PRODUCT PORTFOLIO
  • TABLE 183.HEALTH CATALYST: NET SALES,
  • TABLE 184.HEALTH CATALYST: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.CHRONIC DISEASE MANAGEMENT MARKET SEGMENTATION
  • FIGURE 2.CHRONIC DISEASE MANAGEMENT MARKET,2021-2031
  • FIGURE 3.CHRONIC DISEASE MANAGEMENT MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.CHRONIC DISEASE MANAGEMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.CHRONIC DISEASE MANAGEMENT MARKET,BY TYPE,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF SOLUTIONS CHRONIC DISEASE MANAGEMENT MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF SERVICES CHRONIC DISEASE MANAGEMENT MARKET,2021-2031(%)
  • FIGURE 15.CHRONIC DISEASE MANAGEMENT MARKET,BY DISEASE TYPE,2021(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CARDIOVASCULAR DISEASES  CHRONIC DISEASE MANAGEMENT MARKET,2021-2031(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF DIABETES CHRONIC DISEASE MANAGEMENT MARKET,2021-2031(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF CANCER CHRONIC DISEASE MANAGEMENT MARKET,2021-2031(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF ASTHMA CHRONIC DISEASE MANAGEMENT MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF CHRONIC OBSTRUCTIVE PULMONARY DISORDERS CHRONIC DISEASE MANAGEMENT MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF OTHERS CHRONIC DISEASE MANAGEMENT MARKET,2021-2031(%)
  • FIGURE 22.CHRONIC DISEASE MANAGEMENT MARKET,BY END USER,2021(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF HEALTHCARE PROVIDERS CHRONIC DISEASE MANAGEMENT MARKET,2021-2031(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF HEALTHCARE PAYERS CHRONIC DISEASE MANAGEMENT MARKET,2021-2031(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF OTHERS CHRONIC DISEASE MANAGEMENT MARKET,2021-2031(%)
  • FIGURE 26.CHRONIC DISEASE MANAGEMENT MARKET BY REGION,2021
  • FIGURE 27.U.S. CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION)
  • FIGURE 28.CANADA CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION)
  • FIGURE 29.MEXICO CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION)
  • FIGURE 30.GERMANY CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION)
  • FIGURE 31.FRANCE CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION)
  • FIGURE 32.U.K. CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION)
  • FIGURE 33.ITALY CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION)
  • FIGURE 34.SPAIN CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION)
  • FIGURE 35.REST OF EUROPE CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION)
  • FIGURE 36.JAPAN CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION)
  • FIGURE 37.CHINA CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION)
  • FIGURE 38.AUSTRALIA CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION)
  • FIGURE 39.INDIA CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION)
  • FIGURE 40.SOUTH KOREA CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION)
  • FIGURE 41.REST OF ASIA PACIFIC CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION)
  • FIGURE 42.BRAZIL CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION)
  • FIGURE 43.SAUDI ARABIA CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION)
  • FIGURE 44.SOUTH AFRICA CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION)
  • FIGURE 45.REST OF LAMEA CHRONIC DISEASE MANAGEMENT MARKET,2021-2031($MILLION)
  • FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 50.COMPETITIVE DASHBOARD
  • FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 52.KONINKLIJKE PHILIPS N.V.: NET SALES ,($MILLION)
  • FIGURE 53.COGNIZANT TRIZETTO SOFTWARE GROUP INC,.: NET SALES ,($MILLION)
  • FIGURE 54.CEDAR GATE TECHNOLOGIES.: NET SALES ,($MILLION)
  • FIGURE 55.CASENET, LLC.: NET SALES ,($MILLION)
  • FIGURE 56.CLIEXA, INC.: NET SALES ,($MILLION)
  • FIGURE 57.ALTRUISTA HEALTH.: NET SALES ,($MILLION)
  • FIGURE 58.INFOSYS LTD.: NET SALES ,($MILLION)
  • FIGURE 59.PEGASYSTEMS INC.: NET SALES ,($MILLION)
  • FIGURE 60.EPIC SYSTEMS CORPORATION.: NET SALES ,($MILLION)
  • FIGURE 61.HINDUJA GLOBAL SOLUTIONS LTD.: NET SALES ,($MILLION)
  • FIGURE 62.NXGN MANAGEMENT, LLC.: NET SALES ,($MILLION)
  • FIGURE 63.EXLSERVINGS HOLDINGS, INC.: NET SALES ,($MILLION)
  • FIGURE 64.VIVIFY HEALTH, INC.: NET SALES ,($MILLION)
  • FIGURE 65.ALLSCRIPTS HEALTHCARE, LLC.: NET SALES ,($MILLION)
  • FIGURE 66.MEDECISION.: NET SALES ,($MILLION)
  • FIGURE 67.ZEOMEGA.: NET SALES ,($MILLION)
  • FIGURE 68.HEALTH CATALYST.: NET SALES ,($MILLION)